Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature

Int J Dermatol. 2011 Mar;50(3):287-91. doi: 10.1111/j.1365-4632.2010.04728.x.


Sarcoidosis is a multisystem granulomatous disease that affects multiple organs in adults between 20 and 50 years old. Interferon alpha (IFN-α) is an immunomodulator that has been used in a wide range of diseases, including hepatitis C virus infection, multiple sclerosis, and other types of neoplasias, including leukemia, lymphoma, Kaposi's sarcoma, and melanoma. Standard IFN-α-induced sarcoidosis has been reported, but there are few reports of cutaneous sarcoidosis with pegylated IFN-α therapy. We present a new case of cutaneous sarcoidosis after treatment with pegylated IFN, and a review of the literature.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antiviral Agents / adverse effects
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Male
  • Middle Aged
  • Polyethylene Glycols / adverse effects*
  • Recombinant Proteins
  • Ribavirin / adverse effects*
  • Sarcoidosis / chemically induced*
  • Skin Diseases / chemically induced*


  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a